FDA approves Gammagard Liquid 10% (Baxter) for Multifocal Motor Neuropathy

The FDA has approved Gammagard Liquid 10% [Immune Globulin Infusion (Human)] as a treatment for Mmultifocal Motor Neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States. It was approved for use with MMN patients in Europe in 2011. MMN is associated with a progressive, asymmetric limb weakness mostly affecting the upper limbs, which can lead to significant difficulty with simple manual tasks. Nearly 80 percent of people with MMN are between 20 and 50 years of age at onset of the disease, and men are more frequently affected than women.